Suppr超能文献

为欺骗性安慰剂的使用进行辩护所需的条件。

What it takes to defend deceptive placebo use.

作者信息

Barnhill Anne

机构信息

Johns Hopkins University, USA.

出版信息

Kennedy Inst Ethics J. 2011 Sep;21(3):219-50. doi: 10.1353/ken.2011.0015.

Abstract

A complete defense of deceptive placebo use must address this ethical objection: deceptive placebo use violates patient autonomy, because deceiving a patient about the placebo nature of a proposed treatment prevents her from giving informed consent to the treatment. Unfortunately, this objection isn't always recognized and clearly disambiguated from other ethical concerns. I consider how well several bioethicists who write about placebo use have responded to, or evaded, this objection. I conclude that defenders of deceptive placebo use should, following the lead of Onora O'Neill, argue that deceptive placebo use is compatible with informed consent.

摘要

对使用欺骗性安慰剂的全面辩护必须回应这一伦理质疑

使用欺骗性安慰剂侵犯了患者的自主权,因为在拟议治疗的安慰剂性质方面欺骗患者会妨碍她对该治疗给予知情同意。不幸的是,这一质疑并未总是得到认可,也未与其他伦理问题明确区分开来。我思考了几位撰写有关安慰剂使用文章的生物伦理学家对这一质疑的回应或规避情况。我得出结论,使用欺骗性安慰剂的辩护者应效仿奥诺拉·奥尼尔的做法,主张使用欺骗性安慰剂与知情同意是相容的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验